Format

Send to

Choose Destination
Ann Rheum Dis. 2019 Nov 9. pii: annrheumdis-2019-216030. doi: 10.1136/annrheumdis-2019-216030. [Epub ahead of print]

Adenosine deaminase 2 as a biomarker of macrophage activation syndrome in systemic juvenile idiopathic arthritis.

Author information

1
Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA pui.lee@childrens.harvard.edu pnigrovic@bwh.harvard.edu.
2
Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, United States.
3
Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.
4
Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, United States.
5
RK Mellon Institute for Pediatric Research, Pittsburg, PA, United States.
6
Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
7
Department of Pathology, Brigham and Women's Hospital, Boston, MA, United States.
8
Department of Cardiology, Boston Children's Hospital, Boston, MA, United States.
9
Department of Medicine and Biochemistry, Duke University School of Medicine, Durham, NC, United States.

Abstract

OBJECTIVE:

Macrophage activation syndrome (MAS) is a life-threatening complication of systemic juvenile idiopathic arthritis (sJIA) characterised by a vicious cycle of immune amplification that can culminate in overwhelming inflammation and multiorgan failure. The clinical features of MAS overlap with those of active sJIA, complicating early diagnosis and treatment. We evaluated adenosine deaminase 2 (ADA2), a protein of unknown function released principally by monocytes and macrophages, as a novel biomarker of MAS.

METHODS:

We established age-based normal ranges of peripheral blood ADA2 activity in 324 healthy children and adults. We compared these ranges with 173 children with inflammatory and immune-mediated diseases, including systemic and non-systemic JIA, Kawasaki disease, paediatric systemic lupus erythematosus and juvenile dermatomyositis.

RESULTS:

ADA2 elevation beyond the upper limit of normal in children was largely restricted to sJIA with concomitant MAS, a finding confirmed in a validation cohort of sJIA patients with inactive disease, active sJIA without MAS or sJIA with MAS. ADA2 activity strongly correlated with MAS biomarkers including ferritin, interleukin (IL)-18 and the interferon (IFN)-γ-inducible chemokine CXCL9 but displayed minimal association with the inflammatory markers C reactive protein and erythrocyte sedimentation rate. Correspondingly, ADA2 paralleled disease activity based on serial measurements in patients with recurrent MAS episodes. IL-18 and IFN-γ elicited ADA2 production by peripheral blood mononuclear cells, and ADA2 was abundant in MAS haemophagocytes.

CONCLUSIONS:

These findings collectively identify the utility of plasma ADA2 activity as a biomarker of MAS and lend further support to a pivotal role of macrophage activation in this condition.

KEYWORDS:

adenosine deaminase 2; biomarker; macrophage activation syndrome; systemic juvenile idiopathic arthritis

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center